Edition:
India

Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

12.70USD
18 Apr 2019
Change (% chg)

$0.19 (+1.52%)
Prev Close
$12.51
Open
$12.48
Day's High
$12.83
Day's Low
$12.31
Volume
208,719
Avg. Vol
234,981
52-wk High
$24.45
52-wk Low
$11.64

Latest Key Developments (Source: Significant Developments)

Amneal Announces Agreement With Zentiva To Divest Creo Pharma
Monday, 1 Apr 2019 

April 1 (Reuters) - Amneal Pharmaceuticals Inc ::PRESS RELEASE - AMNEAL ANNOUNCES AGREEMENT WITH ZENTIVA TO DIVEST CREO PHARMA.AMNEAL PHARMACEUTICALS INC - ZENTIVA HAS ACQUIRED CREO PHARMACEUTICALS.  Full Article

Amneal Pharmaceuticals Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing
Saturday, 2 Mar 2019 

March 1 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Amneal Completes Transition Agreement With Amneal To Begin Selling Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL COMPLETES TRANSITION AGREEMENT WITH LANNETT COMPANY TO BEGIN COMMERCIALIZATION OF LEVOTHYROXINE ON DECEMBER 1ST.AMNEAL PHARMACEUTICALS INC - AGREEMENT ACCELERATES AMNEAL'S TIME TO MARKET WITH HIGH VALUE GENERIC.AMNEAL PHARMACEUTICALS - AMNEAL DOES NOT EXPECT TRANSACTION TO HAVE A MATERIAL IMPACT ON ITS FULL YEAR 2018 RESULTS.  Full Article

Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lannett Company Inc ::LANNETT ENTERS INTO AGREEMENT WITH AMNEAL PHARMACEUTICALS FOR LEVOTHYROXINE.LANNETT COMPANY INC - LANNETT LOCKS IN $50 MILLION OF GROSS PROFIT FOR 16-WEEK PERIOD.LANNETT COMPANY INC - LANNETT WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION, OTHER TERMS OF TRANSACTION WERE NOT DISCLOSED.LANNETT COMPANY INC - AGREEMENT ALLOWS LANNETT TO CONTINUE TO RECOGNIZE REVENUE AND EBITDA FOR REMAINDER OF JSP CONTRACT TERM.LANNETT - AMNEAL TO BE CO'S SOLE CUSTOMER FOR LEVOTHYROXINE SODIUM BEGINNING DECEMBER 1, 2018 THROUGH MARCH 23, 2019.  Full Article

Amneal Pharmaceutical's Unit Extends Expiration Dates For Certain Lots Of Generic Adrenaclick Epinephrine Injection
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Amneal Pharmaceuticals Inc ::EXPIRATION DATES FOR CERTAIN LOTS OF GENERIC ADRENACLICK® EPINEPHRINE INJECTION, USP AUTO-INJECTOR EXTENDED TO 20 MONTHS.AMNEAL PHARMACEUTICALS - CO'S UNIT IMPAX LABORATORIES IS EXTENDING EXPIRATION DATES FOR CERTAIN LOTS OF EPINEPHRINE INJECTION, USP AUTO-INJECTOR.  Full Article

Amneal Announces Approval Of Carmustine For Injection Usp, 100 Mg/Vial - Preparing For Launch
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES APPROVAL OF CARMUSTINE FOR INJECTION USP, 100 MG/VIAL - PREPARING FOR LAUNCH.AMNEAL PHARMACEUTICALS INC - RECEIVED FDA APPROVAL FOR A GENERIC VERSION OF BICNU.AMNEAL PHARMACEUTICALS INC - PLANNING TO COMMERCIALIZE ITS CARMUSTINE FOR INJECTION IN NOVEMBER 2018.  Full Article

Amneal Announces FDA Approval And Launch Of Generic Chlorpromazine Hydrochloride Tablets Usp And Approval Of Methylergonovine Maleate Tablets Usp
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES FDA APPROVAL AND LAUNCH OF GENERIC CHLORPROMAZINE HYDROCHLORIDE TABLETS USP AND APPROVAL OF METHYLERGONOVINE MALEATE TABLETS USP.  Full Article

Amneal Announces Partnership With American Regent
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES PARTNERSHIP WITH AMERICAN REGENT ON GENERIC MAKENA® AND PROGRESS ON ITS BUSINESS PLAN WITH ADDITIONAL ANDA APPROVALS AND LAUNCHES.AMNEAL PHARMACEUTICALS INC - WILL DISTRIBUTE A GENERIC VERSION OF MAKENA TO RETAIL CONSORTIUMS.AMNEAL PHARMACEUTICALS INC - RECEIVED APPROVALS FOR TWO NEW TOPICAL PRODUCTS THAT TREAT A VARIETY OF SKIN CONDITIONS.AMNEAL PHARMACEUTICALS INC - WELL-POSITIONED TO ACHIEVE GOAL OF LAUNCHING UP TO 47 NEW PRODUCTS BY END OF YEAR.AMNEAL PHARMACEUTICALS - AMERICAN REGENT WILL MARKET GENERIC VERSION OF MAKENA IN CERTAIN CHANNELS INCLUDING HOSPITAL AND SPECIALTY CHANNELS.AMNEAL PHARMACEUTICALS - ANNOUNCED A 5-YEAR SUPPLY & DISTRIBUTION AGREEMENT WITH AMERICAN REGENT FOR GENERIC ALTERNATIVE TO MAKENA.  Full Article

Amneal Announces Q2 Adjusted Earnings Per Share $0.24
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES SOLID SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $413.8 MILLION VERSUS I/B/E/S VIEW $460.8 MILLION.Q2 ADJUSTED EARNINGS PER SHARE $0.24.Q2 GAAP LOSS PER SHARE $0.15.Q2 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S.UPDATES 2018 FINANCIAL GUIDANCE.SEES 2018 ADJUSTED EPS $0.90 TO $1.00.AMNEAL PHARMACEUTICALS - SEES 2018 CAPEX $80 MILLION TO $100 MILLION.AMNEAL PHARMACEUTICALS - REVISED 2018 ADJUSTED\EPS GUIDANCE PRIMARILY DUE TO DELAYED TIMING OF DELIVERIES OF EPINEPHRINE AUTO-INJECTOR.  Full Article

Amneal Announces Favorable Ruling Regarding Patent Validity For Zomig Nasal Spray
Friday, 29 Jun 2018 

June 29 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES FAVORABLE RULING REGARDING PATENT VALIDITY FOR ZOMIG® (ZOLMITRIPTAN) NASAL SPRAY.AMNEAL PHARMA - PANEL OF THREE CIRCUIT JUDGES AFFIRMED RULING THAT LANNETT FAILED TO PROVE U.S. PATENTS PROTECTING ZOMIG NASAL SPRAY WERE INVALID.  Full Article